Novo Nordisk A/s (NYSE: NVO)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Novo Nordisk A/s Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novo Nordisk A/s Company Info
Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.
News & Analysis
These two healthcare giants defied the bear market last year.
Some stocks are hitting new highs.
Novo Nordisk underestimated demand in 2022, but it's vowing not to make the same mistake this year.
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while.
These stocks have already begun to rally over the past few months.
It would be a major addition to an already rich portfolio.
The number changes quickly.
An obese population could drive competition toward a valuable market.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/04/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
NVO earnings call for the period ending December 31, 2022.
NVO earnings call for the period ending September 30, 2022.
NVO earnings call for the period ending June 30, 2022.
NVO earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.